To evaluate the impact of cryopreservation on immune functions Other
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. A female or male participant aged 18 to 60 years inclusive at the time of the blood draw 2. Willing to participate in blood collection 3. A participant in good health, as confirmed by the participant (self-declaration)
Exclusion criteria
Exclusion criteria: 1. Difficulty providing blood samples 2. A history or evidence of immunodeficiency 3. Use of any prescription medication or NSAIDs within 14 days before blood draw, except for contraceptives 4. Fever at the time of the blood draw (body temperature >38°C) 5. Recent vaccination (within the past 6 months) 6. Pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. NK cell cytotoxicity, assessed by a flow cytometry-based assay using K562 target cells under fresh, post-thaw, and post-thaw with recovery conditions at one timepoint 2. Monocyte phagocytic activity, assessed by uptake of fluorescent bacteria via flow cytometry at one timepoint | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Concentrations of IFN-? and IL-12 measured using ELISA in cryopreserved plasma samples collected at the time of blood draw, in terms of assay feasibility, reproducibility, and sensitivity at one timepoint | — |
Countries
Belgium